Genentech Inc. (South San Francisco...
Genentech Inc. (South San Francisco, CA) and XOMA Ltd (Berkeley, CA) have reported preliminary comes from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous Raptiva (efalizumab) treatment in exposes with moderate-to-severe psoriasis. A total of 339 subdues were enrolled in this continuing contemplation Forty-one percent of ...
|